Skip to content
A young boy in a cowboy hat enjoys riding a horse

The OneGene Program supports your family at every step

Brady has 3 copies of SMN2 gene
Treated at 14 months old

The OneGene Program supports your family at every step

one gene, one team, one purpose

The OneGene Program® is a one-on-one support offering for you and your child who has been prescribed the one-time ZOLGENSMA® (onasemnogene abeparvovec-xioi) treatment.

Once the signed patient consent form and the ZOLGENSMA prescription form are submitted, you'll be enrolled in the OneGene Program and you will meet your Family Ambassador who will be your main, dedicated point of contact. In addition, you will also have the support of the Case Coordinator, who will work closely with your doctor, Family Ambassador, and you to help your child start on ZOLGENSMA.

The OneGene Team members are there for additional support and do not take the place of the medical expertise your doctor provides. For specific medical questions and guidance, please check with your doctor to receive the most accurate and appropriate information.

Family Ambassador

  • Answers any questions you have related to SMA and ZOLGENSMA, and walks you through the steps to prepare for before and after treatment
  • Identifies program resources based on the needs of your child and your family
  • Answers questions you may have about health insurance coverage
  • Provides information about local, regional, and national SMA advocacy organizations and support groups where you can find resources that may be helpful for you and your family on theCure SMA Community Support website

Your Family Ambassador is a reassuring voice to speak with whenever you need the support

Case Coordinator

  • Discusses financial assistance options with you based on your eligibility
  • Answers insurance questions and provides appropriate resources to your doctor
  • Keeps track of ZOLGENSMA treatment from prescription through arrival for your child’s infusion

Your Case Coordinator is there to provide you with additional support and will work with your doctor so you can focus on your child

At the OneGene Program, we have one goal—to support your family throughout the treatment journey with ZOLGENSMA

Enroll in the OneGene Program to learn more and start receiving the support and resources

Call the OneGene Program at 855-441-GENE (4363),
Monday-Friday (8 AM-8 PM ET)

Help with paying for treatment may be available

The OneGene Program may help you find programs or organizations that provide additional financial resources to support you and your family. Your Case Coordinator will share information with you on available financial assistance based on your specific situation, including:

The ZOLGENSMA CopayAssist™ Program for eligible, commercially insured US residents

Novartis Gene Therapies Patient Assistance Program for ZOLGENSMA is available for qualified patients and their families. Contact OneGene for more information

Other independent support foundations that offer financial assistance to eligible patients/families

Discover more informational and educational resources

Explore resources

Important Safety Information

Expand to see more

What is the most important information I should know about ZOLGENSMA?

  • ZOLGENSMA can increase liver enzyme levels and cause acute serious liver injury or acute liver failure which could result in death.
  • Patients will receive an oral corticosteroid before and after infusion with ZOLGENSMA and will undergo regular blood tests to monitor liver function.
  • Contact the patient's doctor immediately if the patient's skin and/or whites of the eyes appear yellowish, if the patient misses a dose of corticosteroid or vomits it up, or if the patient experiences a decrease in alertness.

What should I watch for before and after infusion with ZOLGENSMA?

  • Infections before or after ZOLGENSMA infusion can lead to more serious complications. Caregivers and close contacts with the patient should follow infection prevention procedures. Contact the patient's doctor immediately if the patient experiences any signs of a possible infection such as coughing, wheezing, sneezing, runny nose, sore throat, or fever.
  • Decreased platelet counts could occur following infusion with ZOLGENSMA. Seek immediate medical attention if the patient experiences unexpected bleeding or bruising.
  • Thrombotic microangiopathy (TMA) has been reported to generally occur within the first two weeks after ZOLGENSMA infusion. Seek immediate medical attention if the patient experiences any signs or symptoms of TMA, such as unexpected bruising or bleeding, seizures, or decreased urine output.
  • There is a theoretical risk of tumor development with gene therapies such as ZOLGENSMA. Contact the patient’s doctor and Novartis Gene Therapies, Inc. (1-833-828-3947) if a tumor develops.

What do I need to know about vaccinations and ZOLGENSMA?

  • Talk with the patient's doctor to decide if adjustments to the vaccination schedule are needed to accommodate treatment with a corticosteroid.
  • Protection against influenza and respiratory syncytial virus (RSV) is recommended and vaccination status should be up-to-date prior to ZOLGENSMA administration. Please consult the patient's doctor.

Do I need to take precautions with the patient's bodily waste?

Temporarily, small amounts of ZOLGENSMA may be found in the patient's stool. Use good hand hygiene when coming into direct contact with patient body waste for one month after infusion with ZOLGENSMA. Disposable diapers should be sealed in disposable trash bags and thrown out with regular trash.

What are the possible or likely side effects of ZOLGENSMA?

The most common side effects that occurred in patients treated with ZOLGENSMA were elevated liver enzymes and vomiting.

Indication

What is ZOLGENSMA?

ZOLGENSMA is a prescription gene therapy used to treat children less than 2 years old with spinal muscular atrophy (SMA). ZOLGENSMA is given as a one-time infusion into a vein. ZOLGENSMA was not evaluated in patients with advanced SMA.

The safety information provided here is not comprehensive. Talk to the patient's doctor about any side effects that bother the patient or that don't go away.

You are encouraged to report suspected side effects by contacting the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch, or Novartis Gene Therapies, Inc. at 1-833-828-3947.

Please see the FullPrescribing Information.

Tap or scroll down to read full Important Safety Information and IndicationArrow icon

Important Safety Information

What is the most important information I should know about ZOLGENSMA?

  • ZOLGENSMA can increase liver enzyme levels and cause acute serious liver injury or acute liver failure which could result in death.
  • Patients will receive an oral corticosteroid before and after infusion with ZOLGENSMA and will undergo regular blood tests to monitor liver function.
  • Contact the patient’s doctor immediately if the patient’s skin and/or whites of the eyes appear yellowish, if the patient misses a dose of corticosteroid or vomits it up, or if the patient experiences a decrease in alertness.

What should I watch for before and after infusion with ZOLGENSMA?

  • Infections before or after ZOLGENSMA infusion can lead to more serious complications. Caregivers and close contacts with the patient should follow infection prevention procedures. Contact the patient’s doctor immediately if the patient experiences any signs of a possible infection such as coughing, wheezing, sneezing, runny nose, sore throat, or fever.
  • Decreased platelet counts could occur following infusion with ZOLGENSMA. Seek immediate medical attention if the patient experiences unexpected bleeding or bruising.
  • Thrombotic microangiopathy (TMA) has been reported to generally occur within the first two weeks after ZOLGENSMA infusion. Seek immediate medical attention if the patient experiences any signs or symptoms of TMA, such as unexpected bruising or bleeding, seizures, or decreased urine output.
  • There is a theoretical risk of tumor development with gene therapies such as ZOLGENSMA. Contact the patient’s doctor and Novartis Gene Therapies, Inc. (1-833-828-3947) if a tumor develops.

What do I need to know about vaccinations and ZOLGENSMA?

  • Talk with the patient’s doctor to decide if adjustments to the vaccination schedule are needed to accommodate treatment with a corticosteroid.
  • Protection against influenza and respiratory syncytial virus (RSV) is recommended and vaccination status should be up-to-date prior to ZOLGENSMA administration. Please consult the patient’s doctor.

Do I need to take precautions with the patient’s bodily waste?

Temporarily, small amounts of ZOLGENSMA may be found in the patient’s stool. Use good hand hygiene when coming into direct contact with patient body waste for one month after infusion with ZOLGENSMA. Disposable diapers should be sealed in disposable trash bags and thrown out with regular trash.

What are the possible or likely side effects of ZOLGENSMA?

The most common side effects that occurred in patients treated with ZOLGENSMA were elevated liver enzymes and vomiting.

Indication

What is ZOLGENSMA?

ZOLGENSMA is a prescription gene therapy used to treat children less than 2 years old with spinal muscular atrophy (SMA). ZOLGENSMA is given as a one-time infusion into a vein. ZOLGENSMA was not evaluated in patients with advanced SMA.

The safety information provided here is not comprehensive. Talk to the patient’s doctor about any side effects that bother the patient or that don’t go away.

You are encouraged to report suspected side effects by contacting the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch, or Novartis Gene Therapies, Inc. at 1-833-828-3947.

Please see the Full Prescribing Information.

This website may use cookies to improve the site and your experience. See how Novartis Gene Therapies, Inc. collects, uses, and shares your personal information in our Privacy Policy.

The information provided in this site is intended only for audiences of the United States. This information does not take the place of talking to your healthcare professional about medical conditions and treatments. If you have questions about ZOLGENSMA after reading this information, ask your healthcare professional.

back to top image